A Pancreatic Cancer Drug Moved the Survival Line by Six Months
Revolution Medicines' daraxonrasib nearly doubled median survival in pancreatic cancer versus chemotherapy — the largest gain in a decade, and oncologists are calling it a landmark.
Kenji Nakamura
Bureau: Tokyo
Right Whale Calving Season Closed at 23 — That Is the Best Since 2009
The North Atlantic right whale calving season has officially closed at 23 confirmed calves — a 17-year high that is now a final count, not a projection.
McGill Found One Enzyme That Governs Both Fat-Burning and Bone-Building
McGill researchers publishing in Nature identified glycerol as the molecule that activates TNAP, linking brown fat thermogenesis directly to bone mineralization.
FDA Cleared Expanded Access to Daraxonrasib After Phase 3 Results Showed 13 Months Versus 6.7
FDA cleared expanded access for daraxonrasib after Phase 3 data showed 13.2 versus 6.7 months median overall survival in first-line pancreatic cancer.
Daraxonrasib Cut Pancreatic Cancer's Median Survival Gap by More Than Half
Phase 3 data: 13.2 months median overall survival vs 6.7 months on control — NEJM-published, FDA expanded access cleared.